- Home
- CHCI vs UNCY Comparison
CHCI vs UNCY Comparison
Compare CHCI & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHCI
- UNCY
- Stock Information
- Founded
- CHCI 1985
- UNCY 2016
- Country
- CHCI United States
- UNCY United States
- Employees
- CHCI N/A
- UNCY N/A
- Industry
- CHCI Building operators
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- CHCI Real Estate
- UNCY Health Care
- Exchange
- CHCI Nasdaq
- UNCY Nasdaq
- Market Cap
- CHCI 68.9M
- UNCY 71.8M
- IPO Year
- CHCI 2004
- UNCY 2021
- Fundamental
- Price
- CHCI $10.45
- UNCY $0.60
- Analyst Decision
- CHCI
- UNCY Strong Buy
- Analyst Count
- CHCI 0
- UNCY 2
- Target Price
- CHCI N/A
- UNCY $5.25
- AVG Volume (30 Days)
- CHCI 61.5K
- UNCY 1.2M
- Earning Date
- CHCI 05-13-2025
- UNCY 05-12-2025
- Dividend Yield
- CHCI N/A
- UNCY N/A
- EPS Growth
- CHCI 83.12
- UNCY N/A
- EPS
- CHCI 1.41
- UNCY N/A
- Revenue
- CHCI $51,294,000.00
- UNCY N/A
- Revenue This Year
- CHCI N/A
- UNCY N/A
- Revenue Next Year
- CHCI N/A
- UNCY $1,677.16
- P/E Ratio
- CHCI $7.41
- UNCY N/A
- Revenue Growth
- CHCI 14.70
- UNCY N/A
- 52 Week Low
- CHCI $5.90
- UNCY $0.20
- 52 Week High
- CHCI $14.48
- UNCY $1.29
- Technical
- Relative Strength Index (RSI)
- CHCI 64.30
- UNCY 54.18
- Support Level
- CHCI $9.16
- UNCY $0.45
- Resistance Level
- CHCI $9.15
- UNCY $0.63
- Average True Range (ATR)
- CHCI 0.86
- UNCY 0.06
- MACD
- CHCI 0.11
- UNCY 0.01
- Stochastic Oscillator
- CHCI 90.27
- UNCY 78.95
About CHCI Comstock Holding Companies Inc.
Comstock Holding Co Inc is a developer and manager of mixed-use and transit-oriented properties with operations that are majorly focused on the Washington, D.C. metropolitan area. It provides a range of services such as asset management, property management, development and construction management, and other real estate-related services to its asset-owning clients, composed predominantly of institutional real estate investors, high net worth family offices, financial institutions, and governmental bodies seeking to enhance their surrounding communities by developing real estate through public-private partnerships.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.